Eledon Pharmaceuticals (NASDAQ: ELDN) — Perfil da empresa, notícias e dados financeiros
Eledon Pharmaceuticals develops therapies aimed at addressing transplantation and autoimmune diseases, focused on breakthrough treatments.
Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN) focuses on developing therapies aimed at addressing significant needs in transplantation and autoimmune diseases. Specializing in creating solutions that potentially reduce the need for life-long treatments, Eledon's projects revolve around leveraging scientific and technological advancements to better manage, and possibly cure, conditions that currently have limited treatment options. The company's objective is to pioneer breakthroughs that could transform patient care in its target areas, always pushing the limits of what's possible in the pharmaceutical sector to improve quality of life for those affected by these challenging diseases.
Resumo
Operações
Produtos e/ou serviços de Eledon Pharmaceuticals
- Tegoprubart (AT-1501), an investigational treatment targeting ALS and other autoimmune diseases.
- Research into antibody therapies focusing on organ transplants and autoimmune diseases to prevent rejection and manage symptoms.
- Development of a pipeline for treating neurodegenerative diseases, emphasizing on Alzheimer's and Parkinson's.
- Collaboration with academic institutions to advance research in immunology and chronic diseases.
- Expansion of capabilities in precision medicine, harnessing genetic insights for targeted therapies.
- Investment in technology platforms for drug discovery and development to accelerate the creation of novel therapeutics.
equipe executiva do Eledon Pharmaceuticals
- David-Alexandre C. GrosCEO & Non Independent Director
- Steven N. PerrinPresident, Chief Scientific Officer & Non Independent Director
- Paul Sean LittleChief Financial Officer
- John HerbergerVice President of Technical Operations
- Bryan E. SmithGeneral Counsel, Corporate Secretary & Chief Compliance Officer
- David HovlandChief Regulatory Officer
- Marina EscuderoVP & Head of Clinical Operations
- Sepideh HabibiVP and Head of Safety & Pharmacovigilance
Últimas notícias sobre a Eledon Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Eledon Pharmaceuticals, em USD.
- Cap. de mercado
- 224,3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -83,3 mi | -45,6 mi | |
| 0 | -70,6 mi | -36,2 mi | |
| 0 | -43 mi | -40,3 mi | |
| 0 | -88,4 mi | -88 mi |